TY - JOUR
T1 - The use of a systems approach to increase NAD+ in human participants
AU - Henderson, John D.
AU - Quigley, Sophia N. Z.
AU - Chachra, Shruti S.
AU - Conlon, Nichola
AU - Ford, Dianne
N1 - Funding information: The authors thank Dr Willian Cheung, Northumbria University, for carrying out analysis of samples by LC–MS. The study was co-funded by Northumbria University (studentships to J.D.H. and S.N.Z.Q. and infrastructure support) and Nuchido Ltd. (contribution to studentship for S.N.Z.Q., consumables costs, staff costs of S.S.C.).
PY - 2024/2/1
Y1 - 2024/2/1
N2 - Reversal or mitigation against an age-related decline in NAD+ has likely benefits, and this premise has driven academic and commercial endeavour to develop dietary supplements that achieve this outcome. We used a systems-based approach to improve on current supplements by targeting multiple points in the NAD+ salvage pathway. In a double-blind, randomised, crossover trial, the supplement - Nuchido TIME+® (NT) - increased NAD+ concentration in whole blood. This was associated with an increase in SIRT1 and an increase in nicotinamide phosphoribosyltransferase (NAMPT) in peripheral blood mononucleocytes, lower concentrations of pro-inflammatory cytokines in plasma, including a reduction in interleukin 2 (IL2), a reduction in glycated serum protein and a shift in the glycosylation profile of immunoglobulin G (IgG) toward a younger biological age, all of which are likely to promote a healthier ageing trajectory.
AB - Reversal or mitigation against an age-related decline in NAD+ has likely benefits, and this premise has driven academic and commercial endeavour to develop dietary supplements that achieve this outcome. We used a systems-based approach to improve on current supplements by targeting multiple points in the NAD+ salvage pathway. In a double-blind, randomised, crossover trial, the supplement - Nuchido TIME+® (NT) - increased NAD+ concentration in whole blood. This was associated with an increase in SIRT1 and an increase in nicotinamide phosphoribosyltransferase (NAMPT) in peripheral blood mononucleocytes, lower concentrations of pro-inflammatory cytokines in plasma, including a reduction in interleukin 2 (IL2), a reduction in glycated serum protein and a shift in the glycosylation profile of immunoglobulin G (IgG) toward a younger biological age, all of which are likely to promote a healthier ageing trajectory.
UR - http://www.scopus.com/inward/record.url?scp=85183702814&partnerID=8YFLogxK
U2 - 10.1038/s41514-023-00134-0
DO - 10.1038/s41514-023-00134-0
M3 - Article
SN - 2056-3973
VL - 10
JO - npj Aging and Mechanisms of Disease
JF - npj Aging and Mechanisms of Disease
IS - 1
M1 - 7
ER -